Although mutation of mTOR is rarely reported in cancer, it is a converging point from many oncogenic nodes, such as mutations leading to the activation of the phosphatidyliositoal-3 kinase (PI3K)-Akt pathway and the rat sarcoma (Ras)-driven mitogen-activated protein kinase (MAPK) pathway. The gene discussed is MTOR; the disease is cancer.